ONCOassist

09/03/2026

👉Access the full quiz here: https://bit.ly/EGFR_ONCO_IQ_FB

📝 This week’s ONCO-IQ clinical knowledge quiz focuses on EGFR inhibitor-associated skin toxicities. Comment the right answer.

Explore EGFR inhibitor-associated skin toxicities and other oncology quizzes across multiple indications, now live on ONCOassist.

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

09/03/2026

🚨 Latest Update!

🔷 A biomarker a**lysis from the Phase III CONTINUUM and DIPPER trials developed a machine-learning classifier identifying three metabolic subtypes (MS1–MS3) in locoregionally advanced nasopharyngeal carcinoma (NPC) to better predict response to immunotherapy.

🔷 The findings suggest that metabolic stratification may help guide more personalized immunotherapy strategies, potentially enabling clinicians to identify patients who are more likely to benefit from immune checkpoint–based treatments and improve therapeutic outcomes in NPC.

🔗 Read more: https://bit.ly/ONCOnews09March-04

09/03/2026

🚨 Latest Update!

🔷 ENHERTU® (Trastuzumab Deruxtecan) has been granted Priority Review by the U.S. FDA as a potential post-neoadjuvant treatment for patients with HER2-positive early breast cancer, highlighting its potential role in addressing residual disease following initial therapy.

🔷 The application is based on the Phase III DESTINY-Breast05 trial, where ENHERTU reduced the risk of invasive disease recurrence or death by 53% vs T-DM1 (HR 0.47), with 3-year Invasive Disease Free Survival (IDFS) of 92% vs 84%, supporting its potential to become a new post-neoadjuvant standard of care.

🔗 Read more: https://bit.ly/ONCOnews09March-03

09/03/2026

🚨 Latest Update!

🔷 The European Commission has approved Retifanlimab (Zynyz) in combination with Carboplatin and Paclitaxel for the first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the a**l ca**l (SCAC), marking the first systemic treatment for advanced SCAC in Europe.

🔷 Approval is based on the Phase III POD1UM-303 trial, where the combination reduced the risk of progression or death by 37% and improved median PFS to 9.3 months vs 7.4 months with chemotherapy alone, with no new safety signals reported.

🔗 Read more: https://bit.ly/ONCOnews09March-02

09/03/2026

🚨 Latest 3 Update!

🔷 Roche reported Phase III persevERA results evaluating Giredestrant + Palbociclib in ER-positive, HER2-negative advanced breast cancer. The trial did not meet its primary endpoint of significantly improving progression free survival (PFS) vs Letrozole + Palbociclib, though a numerical PFS improvement was observed.

🔷 Development of Giredestrant continues across settings, including evERA in advanced disease (NDA accepted by the FDA) and lidERA in early breast cancer, with submission planned soon.

🔗 Read more: https://bit.ly/ONCOnews09Mar-01

06/03/2026

🚨 Latest Update!

🔷 The FDA has approved teclistamab in combination with daratumumab hyaluronidase-fihj for patients with relapsed or refractory multiple myeloma, expanding treatment options in the later-line setting.

🔷 Based on the MajesTEC-3 trial, this combination brings together a BCMA-targeted bispecific antibody and CD38-directed therapy, offering a novel dual-targeted approach for patients who have received prior lines of therapy.

🔗 Read more: https://bit.ly/ONCOnews06-Mar-01

05/03/2026

🎙️New Episode | Expert Insights - EP 1.

In this episode of Oncology Spotlight - Expert Insights, Dr Yüksel ÜRÜN reviews key studies from ASCO GU 2026 across bladder, kidney, and prostate cancer, including:

• EV + pembrolizumab in muscle-invasive bladder cancer

• Belzutifan-based combinations in renal cell carcinoma

• PARP inhibitor combinations in metastatic prostate cancer

🎙️ Watch the full episode here: https://youtu.be/-J4ztmDHYPA

A concise breakdown of the data and its clinical implications.

Download the ONCOassist app:

📥 iOS: https://apple.co/4iuMxfS

📥 Android: https://bit.ly/oncoassistonandroid

📥Webapp: https://bit.ly/ONCOassistOnWeb

🌐 Explore ONCOassist – clinical tools for oncology professionals: https://oncoassist.com/

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! 🔬In this episode of Oncology Spot...

04/03/2026

👉Access the full Genitourinary Cancers quiz here: https://bit.ly/GEUR_ONCO_IQ_FB

🔊Hear from Dr Akash M. as he shares why this ONCO-IQ on Genitourinary Cancers, developed in collaboration with the International Urology Cancer Summit, cannot be missed!

Register for IUCS 2026 here: https://urologycancersummit.org/

Giuseppe Banna Dr. Suleka AR Lakshmi Ramachandran Ravindran Kanesvaran

04/03/2026

🚨 Latest Update!

🔷 Pirtobrutinib (Jaypirca) receives approval from China’s National Medical Products Administration for relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).

🔷 Based on results from the phase 3 BRUIN CLL-321 trial, this treatment expands options for patients progressing after prior BTK inhibitor therapy, marking a key milestone in hematologic oncology.

🔗 Read more: https://bit.ly/ONCOnews04-Mar-01

03/03/2026

📣Introducing Oncology Spotlight - Expert Insights hosted by Dr Yüksel ÜRÜN.

A new focused video series from ONCOassist® is built to deliver high-value clinical conversations with leading voices in oncology.

Expect thoughtful discussions on:

• Guideline evolution

• Trial interpretation

• Drug access & equity

• AI & precision oncology

🎙️ First episode drops soon.

Follow the page and stay tuned.

03/03/2026

🚨 Latest Approval Update!

🔷 The FDA has accepted the New Drug Application (NDA) for Rusfertide, a first-in-class hepcidin mimetic and granted Priority Review, accelerating its regulatory pathway in polycythemia vera.

🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.

🔗 Read more: https://bit.ly/ONCOnews03-Mar-01